Office of Professional Education

Respiratory Medicine Updates: A Virtual Clinical Community

Our Next Session is July 26-27, 2022 • CME Credit for Zoom Webinar and Twitter Chat Participants

Article: Coming Soon!

  • Article Summary for July: Will be posted a week prior to the webinar.

  • Zoom Webinar with CME credit: REGISTER.
    • Tuesday, July 26, 2022
    • 11:30 am (PT) / 12:30 pm (MT) / 1:30 pm (CT) / 2:30 pm (ET)
    • 30-minutes
    • Expert faculty summarize a journal article and lead an academic and peer discussion with Q&A time.

  • Twitter Chat @NJHealthMedEd with CME credit: Add to Calendar
    • Wednesday, July 27, 2022
    • 6:00 pm (PT) / 7:00 pm (MT) / 8:00 pm (CT) / 9:00 pm (ET)
    • 30-minutes
    • Expert faculty lead the Chat about the article summary to facilitate an academic and peer discussion with Q&A.
    • Go to Twitter, type in #NTMTwitterJC and click on the “Latest” tab
    • Please use this hashtag when posting: #NTMTwitterJC
    • Twitter Chat Instructions
    • Follow us on Twitter @NJHealthMedEd

Previous NTM Journal Club Sessions:

  • June 28-29, 2022
    • June 2022 Article Summary: Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022 May 26;185(11):1860-1874.e12. doi: 10.1016/j.cell.2022.04.024. Epub 2022 May 13. PMID: 35568033. View here.
    • Recorded Zoom Webinar available soon on VuMedi.
  • May 24-25, 2022
    • May 2022 Article Summary: Genomic Analysis of a Hospital-Associated Outbreak of Mycobacterium abscessus: Implications on Transmission. J Clin Microbiol. 2022 Jan 19;60(1):e0154721. doi: 10.1128/JCM.01547-21. Epub 2021 Oct 27. PubMed PMID: 34705540; PubMed Central PMCID: PMC8769749. View here.
    • Recorded Zoom Webinar on VuMedi.
  • April 26-27, 2022
    • April 2022 Article Summary: Mycobacterium abscessus biofilms have viscoelastic properties which may contribute to their recalcitrance in chronic pulmonary infections. Sci Rep. 2021 Mar 3;11(1):5020. doi: 10.1038/s41598-021-84525-x. PMID: 33658597. View here.
    • Recorded Zoom Webinar on VuMedi.
  • March 29-30, 2022
    • March 2022 Article Summary: Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection. J Cyst Fibros. 2020 Mar;19(2):225-231. doi: 10.1016/j.jcf.2019.05.002. Epub 2019 May 23. PMID: 31129068. View here.
    • Recorded Zoom Webinar on VuMedi.
  • February 22-23, 2022
    • February 2022 Article Summary: Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus. Matt D Johansen, Matthéo Alcaraz, Rebekah M Dedrick, Françoise Roquet-Banères, Claire Hamela, Graham F Hatfull, Laurent Kremer. s Model Mech. 2021 Sep 1;14(9):dmm049159. doi: 10.1242/dmm.049159. View here.
    • Recorded Zoom Webinar on VuMedi.
  • January 25-26, 2022
    • January 2022 Article Summary: Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections. Open Forum Infectious Diseases, Volume 8, Issue 2, February 2021, ofab002, View here.
    • Recorded Zoom Webinar on VuMedi.
  • November 30, 2021
    • November 2021 Article Summary: Airway Clearance Techniques in Bronchiectasis: Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry. Chest, Volume 158, Issue 4, 2020, Pages 1376-1384, ISSN 0012-3692, View here.
    • Recorded Zoom Webinar on VuMedi.
  • October 26-27, 2021
    • October 2021 Article Summary: Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure. Griffith DE, et al; CONVERT Study Group.Chest. 2021 Sep;160(3):831-842. DOI: 10.1016/j.chest.2021.03.070. View here.
    • Recorded Zoom Webinar on VuMedi.
  • September 28-29, 2021
    • September 2021 Article Summary: Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis, N Engl J Med 2020; 383:2127-2137, DOI: 10.1056/NEJMoa2021713. View here.
    • Recorded Zoom Webinar on VuMedi.
  • August 24-25, 2021
    • August 2021 Article Summary: Amikacin liposome inhalation suspension for Treatment-Refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Repir Crit Care Med 2018; 198: 1559-1569. View here.
    • Recorded Zoom Webinar on VuMedi.

Target Audience:

Pulmonologists, Infectious Disease Physicians, Primary Care and Family Medicine Physicians, Physician Assistants, and Advanced Practice Nurses who treat patients with NTM.


Program Chairs:

Charles L Daley MD

Charles L. Daley, MD
Chief, Division of Mycobacterial and Respiratory Infections
Professor of Medicine
University of Colorado Denver
National Jewish Health
Denver, CO

Shannon H. Kasperbauer MD Shannon H. Kasperbauer, MD
Associate Professor of Medicine
Division of Mycobacterial and Respiratory Infections
National Jewish Health
University of Colorado Denver
Denver, CO


Learning Objectives:

Upon completion of this activity, the participant will be better able to:

  • Apply critical thinking for research analysis in the review of new data and guidelines in NTM.

  • Utilize increased awareness and understanding of research, evidence and best practices to inform clinical practice in NTM.

  • Support an online community of practitioners to share key insights, latest research, and treatment strategies for patients with NTM.



For questions, please call the Office of Professional Education at National Jewish Health at 303.398.1000 or 800.844.2305, or email


Accreditation and Designation Statements:

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Jewish Health designates each live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Twitter Chats
National Jewish Health designates each Other activity (social media discussion) for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Supported by an Educational Grant from Insmed.